by Clinical Neuropsychologist Online | Tuesday, August 18, 2026 | Dementia
Abstract INTRODUCTION Neuroimaging studies report associations of amyloid beta (Aβ) positron emission tomography (PET) with [18F](S)-(2-methylpyrid-5-yl)-6-[(3-fluoro-2-hydroxy)propoxy]quinoline ([18F]SMBT-1), a novel reactive astrogliosis surrogate radiotracer with...
by Clinical Neuropsychologist Online | Friday, August 14, 2026 | Dementia
Overview of the study design and analytical workflow. Plasma samples from cognitively unimpaired (CU) participants were analyzed to evaluate progression to symptomatic Alzheimer’s disease (AD), and additional analyses examined progression from mild cognitive...
by Clinical Neuropsychologist Online | Friday, August 14, 2026 | Dementia
Abstract INTRODUCTION Amyloid-lowering antibodies are associated with neuroanatomical volume changes. This study aims to disentangle the contributions of amyloid-related imaging abnormalities (ARIA) and amyloid clearance to these changes. METHODS Data from the...
by Clinical Neuropsychologist Online | Friday, August 14, 2026 | Dementia
Abstract INTRODUCTION Astrocyte dysfunction is central to Alzheimer’s disease (AD), yet expression patterns of astrocytic markers remain poorly defined. We measured Aquaporin-4 (AQP4) and glial fibrillary acidic protein (GFAP) in post-mortem frontal cortex of AD...
by Clinical Neuropsychologist Online | Friday, August 14, 2026 | Dementia
Dementia, Ahead of Print. Non-pharmacological interventions are widely recognised as essential components of dementia care. However, many cognitive activities lack cultural relevance and are difficult to integrate into everyday care practice. Design-driven approaches...
by Clinical Neuropsychologist Online | Thursday, August 13, 2026 | Dementia
Abstract INTRODUCTION APOE ε4 is the strongest common genetic risk factor for Alzheimer’s disease (AD), yet many carriers remain cognitively unimpaired into late life. We tested whether protected ε4-first plasma proteomics could identify proteins associated with...
